Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

COVID-19 vaccines can cause mild to moderate skin reactions, mostly after the first dose.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

A patient with complete hair loss regrew all her hair using tofacitinib.

Choosing the right recall period for patient feedback is important for accurate data and depends on the disease, symptom changes, and patient impact.

Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.

Hair loss and polyneuropathy improved, but severe vision impairment persisted.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Lung cancer patients on immunotherapy and chemotherapy often experience severe fatigue, drowsiness, and appetite loss.

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.

Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

COVID-19 can trigger a relapsing form of hair loss, requiring long-term treatment strategies.

Post-exposure syndromes are persistent conditions caused by past exposures, needing unique interventions.

Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.

Persistent hyperparathyroidism doesn't stop rickets healing or phosphate level normalization in VDDR2A.

The paper suggests that telogen effluvium, a type of hair loss, may be a long-lasting condition triggered by stress or illness in people whose hair growth is unusually synchronized.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Hair loss can happen after severe H1N1 flu but usually grows back in 4 months.

Long-COVID symptoms like fatigue, cognitive issues, and mobility problems can last 6-12 months but are less common after milder illness.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.